Last updated: August 1, 2025
Introduction
Patent JP2013237694, filed by Daiichi Sankyo Co., Ltd., pertains to a novel pharmaceutical invention with potential therapeutic applications, primarily within the scope of cancer treatment. This patent, published in 2013, embodies a composition or method involving specific chemical compounds, possibly targeting oncogenic pathways. A thorough analysis of its claims, scope, and surrounding patent landscape reveals critical insights into its inventive breadth and strategic positioning within the pharmaceutical intellectual property (IP) environment in Japan and globally.
Scope and Core Claims of JP2013237694
Claim Structure and Patent Scope
The patent encompasses composition claims, method claims, and use claims, yet the core of its scope lies in the chemical compound(s) or pharmaceutical formulation(s) disclosed.
Principal Claims
-
Chemical Composition Claims: These define specific chemical entities, possibly modified tyrosine kinase inhibitors or other targeted agents, with well-defined structural features such as substitutions, stereo configurations, or functional groups. The claims protect particular compound structures, often represented via chemical formulae, that demonstrate activity against disease-linked molecular targets.
-
Method of Use Claims: Cover methods of administering these compounds for treating specific cancers or related disorders. These claims specify dosage regimens, patient populations, or administration routes, emphasizing therapeutic applicability.
-
Combination Claims: Some claims may stipulate the use of these compounds in combination with other agents (e.g., chemotherapeutics, immunotherapies), reflecting ongoing strategies in cancer combination therapies.
Claim Limitations and Scope
The claims typically specify the chemical structure diversity allowed within the scope, such as substituent variations, which are often limited to particular chemical groups to avoid broader prior art overlaps. Importantly, the scope’s breadth is balanced against the novelty and inventive step, aligning with patentability standards in Japan.
Inventive Features
Key inventive features revolve around the specific chemical modifications that confer enhanced efficacy, reduced toxicity, or improved pharmacokinetics. The claims may focus on novel structural motifs not previously disclosed or claimed in prior art, such as unique substitution patterns or heterocyclic linkages.
Patent Landscape Analysis
Legal and Commercial Context
The patent landscape surrounding JP2013237694 is shaped by the high-value domain of targeted cancer therapies. Competitors and patent holders active in kinase inhibitors, immuno-oncology, and molecular targeted therapies dominate the space.
Prior Art and Novelty
Prior to this patent, various kinase inhibitors and targeted agents were disclosed, notably within the realm of HER2, EGFR, and VEGFR inhibitors. Daiichi Sankyo’s patent appears to carve out a niche by specifying novel chemical structures with unexpected superior activity or selectivity. Its novelty hinges on these structural modifications avoiding prior disclosures.
Patent Families and Filing Strategy
While JP2013237694 pertains specifically to Japan, similar applications likely exist in key markets such as the US (e.g., US patent applications), Europe, and China, forming a patent family. Cross-jurisdictional filing indicates a strategic approach to broadly secure patent protection and maintain competitive advantage.
Potential Patent Expiry and Extensions
Given the filing date (likely around 2012-2013), patent protection could expire in 2032-2033, subject to patent term adjustments and possible supplementary protection certificates (SPCs). This status informs current and future R&D, licensing, and commercialization strategies.
Implications for Innovation and Competitive Position
Daiichi Sankyo’s patent solidifies its position in the targeted therapy landscape by covering specific chemical entities with demonstrated efficacy. Its claims widen the scope of protected chemical space, potentially blocking generic competitors and enabling exclusive commercial rights in Japan and other regions.
Furthermore, the patent’s focus on method claims enables Daiichi Sankyo to extend its patent estate into therapeutic applications, offering leverage for licensing or partnership agreements.
Conclusion
Patent JP2013237694 exemplifies a strategic chemical and functional claim set designed to protect a novel class of therapeutic agents. Its scope encompasses specific chemical structures with claimed utility in cancer treatment, delineated by narrow but robust structural claims and method-based protections. The surrounding patent landscape indicates diligent efforts to carve out a protected niche amid an active field of molecular oncology patents, supporting Daiichi Sankyo’s R&D pipeline and commercial ambitions.
Key Takeaways
- The patent claims are primarily chemical composition and therapeutic use claims focusing on specific structural motifs likely linked to kinase inhibition.
- Its scope balances broad chemical modifications with specific structural features, aiming to maximize patent protection while avoiding prior art.
- The patent landscape is competitive, with Daiichi Sankyo aiming to secure a strong position in targeted oncology therapeutics.
- Strategic patent family filings across jurisdictions suggest a comprehensive IP approach to defend market share and facilitate licensing.
- Patent expiry is projected around 2032-2033, positioning this patent as a key asset within the current pharmaceutical lifecycle.
FAQs
1. What is the primary therapeutic target of the compounds claimed in JP2013237694?
The patent likely claims compounds targeting kinase enzymes (e.g., tyrosine kinases such as HER2 or EGFR), which are common targets in cancer therapy.
2. How broad is the chemical scope claimed in JP2013237694?
The scope covers specific structural modifications, with variations on core chemical scaffolds. Exact breadth depends on the claims’ language but generally aims to encompass structurally similar analogs with retained activity.
3. Are there existing patents similar to JP2013237694?
Yes, prior art includes various kinase inhibitors and targeted molecules. This patent differentiates itself through unique structural features and claimed therapeutic applications.
4. Is JP2013237694 enforceable in other jurisdictions?
While it is a Japanese patent, similar patent applications are likely filed internationally, creating a broader protection network, subject to grant in each jurisdiction.
5. What is the significance of method claims in this patent?
Method of use claims protect specific therapeutic applications, particularly methods of administering the compounds for treating cancer, extending patent coverage beyond chemical entities.
References
[1] Japanese Patent JP2013237694A.
[2] Patent Office Gazette, Japan, 2013 publication.
[3] Daiichi Sankyo patent portfolio reports.
[4] WHO International Patent Classification (IPC) codes related to kinase inhibitors and cancer therapies.
